Investigating how oxidative stress and antioxidant treatment regulate blood sugar levels.

Not Applicable

• Conditions: Metabolic and Endocrine; Metabolic and Endocrine - Normal metabolism and endocrine development and function

• Registration Number: ACTRN12620000187943
• Lead Sponsor: Deakin University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-19
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Inclusion Criteria.
1.Aged 18–40 years old
2.Normal weight (BMI 18-27 kg/m2).
3.Normotensive (seated brachial blood pressure <140/90 mmHg).
4.Have given signed informed consent to participate in the study.

Exclusion Criteria

Exclusion Criteria.
1.Age <18 years or >40 years.
2.Underweight, Overweight or Obese with a BMI <18 kg/m2 or >30 kg/m2.
3.Known allergy to eggs.
4.Cardiometabolic diseases including diabetes, cardiovascular disease, or metabolic syndrome.
5.History of myocardial infarction or stroke.
6.Exercise capacity limited by a factor other than claudication, for example:
a.Coronary artery disease (angina pectoris)
b.Pulmonary disease
c.Arthritis or other musculoskeletal complication
7.Critical limb ischaemia including peripheral artery disease or previous revascularisation or other surgical treatment for peripheral artery disease.
8.Self-reported history of microvascular disease (retinopathy, nephropathy or neuropathy).
9.History of malignancy within past 5 years (except for non-melanoma skin cancers).
10.Identification of any medical condition requiring immediate therapeutic intervention.
11.Uncontrolled hypertension (resting brachial blood pressure =160/100 mmHg).
12.Current smoker or previous smoker (within the last 12 months).
13.History of severe liver disease.
14.Elective major surgery during the course of the study.
15.Pregnancy/lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome is change in insulin sensitivity as measured via a 3-hour euglycaemic hyperinsulinemic clamp.[Insulin sensitivity will be measured in the final 3-hours of lipid infusion and post-exercise recovery period (both with and without antioxidant infusion).]

Secondary Outcome Measures

Name	Time	Method
Change in F2-isoprostanes measured in blood.[F2-isoprostanes will be measured at baseline (prior to exercise and lipid infusion), 30 minutes during exercise and lipid infusion, immediately after the 1 hour exercise session and 1 hour of lipid infusion, and at 30 minute intervals throughout the 5 hour post-exercise recovery period and lipid infusion session.]